Maintenance Chemotherapy for Patients with Rhabdomyosarcoma

Area of Science:

• Pediatric Oncology
• Medical Oncology
• Cancer Research

Background:

• Maintenance chemotherapy (MC) involves prolonged, low-intensity chemotherapy to sustain tumor remission.
• Rhabdomyosarcoma (RMS) is a significant pediatric cancer requiring effective treatment strategies.
• Previous studies suggest potential benefits of MC in specific RMS patient groups.

Purpose of the Study:

• To update findings from the RMS2005 trial on the efficacy of MC in high-risk localized RMS.
• To review and discuss existing literature on MC applications in rhabdomyosarcoma.
• To identify areas for future research in MC for RMS treatment.

Main Methods:

• Analysis of updated outcomes from the RMS2005 trial comparing patients who received MC versus those who did not.
• Systematic literature search for studies on MC in RMS, including randomized trials and non-randomized studies.
• Evaluation of MC feasibility and tolerability in relapsed RMS cases.

Main Results:

• The RMS2005 trial showed superior outcomes for patients receiving MC, with higher 5-year disease-free survival (78.1% vs. 70.1%) and overall survival (85.0% vs. 72.4%).
• A review identified seven papers on MC in RMS, but only one randomized trial failed to show an advantage for a specific MC regimen.
• Non-randomized studies indicated better results with MC compared to high-dose chemotherapy, including in metastatic patients, and demonstrated feasibility in relapsed RMS.

Conclusions:

• MC, particularly with vinorelbine and low-dose cyclophosphamide, appears to improve survival in high-risk localized RMS.
• Evidence for MC in RMS is mixed, with varying results depending on the regimen and study design.
• Further investigation is required to determine optimal MC drug combinations and treatment durations for RMS, with ongoing trials aiming to address these questions.